The virtual Lymphoma Hub Satellite Symposium, at this year's European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, brought together an international panel of experts to discuss the management and treatment of patients with relapsed and/or refractory (R/R) lymphoma. Here, Professor Francesc Bosch, University Hospital Vall d'Hebron, Barcelona, ES, outlines how he would manage a patient with R/R chronic lymphocytic leukemia (CLL) following relapse to venetoclax + rituximab.